Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064066 | 1.00 | ERN1 (0.54) | ERN1TYRTRIM24TRIM33CISD1 | |
| SCHEMBL18927374 | 0.91 | ERN1 (0.54) | ERN1TYRTRIM24TRIM33CISD1 | |
| SCHEMBL17807916 | 0.88 | ERN1 (0.56) | ERN1TYRTRIM24TRIM33CDK1 | |
| SCHEMBL6782431 | 0.86 | ERN1 (0.48) | ERN1TRIM24TRIM33CISD1PRKDC | |
| SCHEMBL17660183 | 0.82 | ERN1 (0.52) | ERN1TYRTRIM24TRIM33CDK1 | |
| SCHEMBL680308 | 0.81 | ERN1 (0.48) | ERN1TRIM24TRIM33CISD1PRKDC | |
| SCHEMBL29616071 | 0.80 | ERN1 (0.44) | ERN1TRIM24TRIM33CISD1 | |
| SCHEMBL29743757 | 0.80 | ERN1 (0.48) | ERN1TYRTRIM24TRIM33PRKDC | |
| SCHEMBL31055919 | 0.80 | ERN1 (0.48) | ERN1TYRTRIM24TRIM33CDK1 | |
| SCHEMBL874654 | 0.80 | ERN1 (0.48) | ERN1TYRTRIM24TRIM33CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110937986-B | Compound synthesis method and application in field of insulin resistance improving medicines | 深圳市灵兰生物医药科技有限公司 | 2022-09-06 | — | — | CN | claimed |
| US-20250144253-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2025-05-08 | — | — | US | disclosed |
| CN-117986158-A | Substituted biphenyl compound, preparation method and application | 云南大学 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023130587-A1 | WATER-SOLUBLE METHYLBENZENE ETHER DERIVATIVE, POSITRON NUCLIDE PROBE AND NUCLIDE MARKER, AND PREPARATION METHODS THEREFOR AND USES THEREOF | 四川大学华西医院 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023104744-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | HELMHOLTZ-ZENTRUM DRESDEN-ROSSENDORF E.V. (DE) | 2023-06-15 | — | — | WO | disclosed |
| CN-110937986-B | Compound synthesis method and application in field of insulin resistance improving medicines | 深圳市灵兰生物医药科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-109153626-B | Preparation method of 2-hydroxy-4- (2, 3-disubstituted benzyloxy) -5-substituted benzaldehyde derivative | 天津红日药业股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| EP-3459925-B1 | METHOD FOR PREPARING 2-HYDROXYL-4-(2, 3-DISUBSTITUTED BENZYLOXY)-5-SUBSTITUTED BENZALDEHYDE DERIVATIVE | TIANJIN CHASE SUN PHARMACEUTICAL CO LTD (CN) | 2021-08-11 | — | — | EP | disclosed |
| CN-108069929-B | 3-substituted coumarin derivative and application thereof, and GPR35 receptor agonist | 中国科学院大连化学物理研究所 | 2021-06-15 | — | — | CN | disclosed |
| WO-2021043116-A1 | BIPHENYL COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国药科大学 | 2021-03-11 | — | — | WO | disclosed |
| EP-1980560-B1 | C-glycoside derivatives for the treatment of diabetes | ASTELLAS PHARMA INC (JP) | 2011-05-25 | — | — | EP | disclosed |
| US-7772407-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1980560-A2 | C-glycoside derivatives for the treatment of diabetes | Astellas Pharma Inc. (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1609785-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | Astellas Pharma Inc. (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | ERN1 1131/4885TYR 3202/4885TRIM24 3880/4885 |
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | ERN1 1131/4885TYR 3202/4885TRIM24 3880/4885 |
| US-20090069252-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | SLC5A1, SLC5A2, SLC2A1 | ERN1 1131/4885TYR 3202/4885TRIM24 3880/4885 |
| US-20250144253-A1 | 3-((3-([1,1'-BIPHENYL]-3-YLMETHOXY)PHENOXY)METHYL)BENZONITRILE DERIVATIVES AND THE USE THEREOF | CYP4B1, UGT2B7, UGT1A4 | ERN1 2943/4885TYR 435/4885TRIM24 2983/4885 |
| US-20080269218-A1 | Novel Hsp90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | ERN1 703/4885TYR 2523/4885TRIM24 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.